Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Other

4

Possibly Marketed Outside US

2

US Previously Marketed

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

GABA-A receptor; anion channel

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

4

1929

2

2012

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Insomnia

2

Preoperative sedation

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Preventing

2

Primary

2

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Shonle, H.A.

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

8

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

8

EPA CompTox

8

FDA UNII

8

PUBCHEM

8

ECHA (EC/EINECS)

7

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

NERVOUS SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

PSYCHOLEPTICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

HYPNOTICS AND SEDATIVES

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Barbiturates, plain

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

4

Salts, Hydrates, Esters, etc.

4

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 8 of 8 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

SODIUM CYANOBOROHYDRIDE

C4I8C58P9T

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

METHYLAMINE

BSF23SJ79E

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

SECOBARBITAL SODIUM

XBP604F6UM

Export Data
Search for Structure

Status:

US Previously Marketed

First marketed in 1929

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

GABA-A receptor; anion channel

Conditions:

Preoperative sedation

Secobarbital sodium, a barbiturate, is FDA approved for the treatment of insomnia and for pre-anesthetic use. This drug binds at a distinct site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- i...

onopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. Adverse reactions are drowsiness, lethargy, hangover, paradoxical excitement in elderly patients, somnolence. Rifampin may decrease secobarbital levels by increasing metabolism.

CHLOROACETIC ACID

5GD84Y125G

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 2012

Class (Stereo):

CHEMICAL (ACHIRAL)

Methylammonium bromide

NDV5PY4944

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

METHYLAMINE HYDROCHLORIDE

M439EX322K

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

SECOBARBITAL

1P7H87IN75

Export Data
Search for Structure

Status:

US Previously Marketed

First marketed in 1929

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

GABA-A receptor; anion channel

Conditions:

Preoperative sedation

Secobarbital sodium, a barbiturate, is FDA approved for the treatment of insomnia and for pre-anesthetic use. This drug binds at a distinct site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- i...

onopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. Adverse reactions are drowsiness, lethargy, hangover, paradoxical excitement in elderly patients, somnolence. Rifampin may decrease secobarbital levels by increasing metabolism.

SODIUM CHLOROACETATE

8D9PZU6L69

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 2012

Class (Stereo):

CHEMICAL (ACHIRAL)

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1